<?xml version="1.0" encoding="UTF-8"?>
<document id="DrugDDI.d222" origId="Bortezomib"><sentence id="DrugDDI.d222.s0" origId="s0" text="No formal drug interaction studies have been conducted with VELCADE."><entity id="DrugDDI.d222.s0.e0" origId="s0.p4" charOffset="60-67" type="drug" text="VELCADE"/></sentence><sentence id="DrugDDI.d222.s1" origId="s1" text="In vitro studies with human liver microsomes indicate that bortezomib is primarily a substrate for cytochrome P450 3A4, 2C19, and 1A2."><entity id="DrugDDI.d222.s1.e0" origId="s1.p8" charOffset="59-69" type="drug" text="bortezomib"/><entity id="DrugDDI.d222.s1.e1" origId="s1.p11" charOffset="99-118" type="drug" text="cytochrome P450 3A4"/><pair id="DrugDDI.d222.s1.p0" e1="DrugDDI.d222.s1.e0" e2="DrugDDI.d222.s1.e1" interaction="?"/></sentence><sentence id="DrugDDI.d222.s2" origId="s2" text="Patients who are concomitantly receiving VELCADE and drugs that are inhibitors or inducers of cytochrome P450 3A4 should be closely monitored for either toxicities or reduced efficacy ."><entity id="DrugDDI.d222.s2.e0" origId="s2.p20" charOffset="41-48" type="drug" text="VELCADE"/><entity id="DrugDDI.d222.s2.e1" origId="s2.p22" charOffset="53-58" type="drug" text="drugs"/><entity id="DrugDDI.d222.s2.e2" origId="s2.p28" charOffset="94-113" type="drug" text="cytochrome P450 3A4"/><pair id="DrugDDI.d222.s2.p0" e1="DrugDDI.d222.s2.e0" e2="DrugDDI.d222.s2.e1" interaction="?"/><pair id="DrugDDI.d222.s2.p1" e1="DrugDDI.d222.s2.e0" e2="DrugDDI.d222.s2.e2" interaction="?"/><pair id="DrugDDI.d222.s2.p2" e1="DrugDDI.d222.s2.e1" e2="DrugDDI.d222.s2.e2" interaction="?"/></sentence><sentence id="DrugDDI.d222.s3" origId="s3" text="During clinical trials, hypoglycemia and hyperglycemia were reported in diabetic patients receiving oral hypoglycemics."><entity id="DrugDDI.d222.s3.e0" origId="s3.p46" charOffset="100-118" type="drug" text="oral hypoglycemics"/></sentence><sentence id="DrugDDI.d222.s4" origId="s4" text="Patients on oral antidiabetic agents receiving VELCADE treatment may require close monitoring of their blood glucose levels and adjustment of the dose of their antidiabetic medication."><entity id="DrugDDI.d222.s4.e0" origId="s4.p48" charOffset="17-36" type="drug" text="antidiabetic agents"/><entity id="DrugDDI.d222.s4.e1" origId="s4.p50" charOffset="47-54" type="drug" text="VELCADE"/><entity id="DrugDDI.d222.s4.e2" origId="s4.p58" charOffset="160-172" type="drug" text="antidiabetic"/><pair id="DrugDDI.d222.s4.p0" e1="DrugDDI.d222.s4.e0" e2="DrugDDI.d222.s4.e1" interaction="?"/><pair id="DrugDDI.d222.s4.p1" e1="DrugDDI.d222.s4.e0" e2="DrugDDI.d222.s4.e2" interaction="?"/><pair id="DrugDDI.d222.s4.p2" e1="DrugDDI.d222.s4.e1" e2="DrugDDI.d222.s4.e2" interaction="?"/></sentence><sentence id="DrugDDI.d222.s5" origId="s5" text="Drug Laboratory Test Interactions None known."/></document>